ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 67 citations in OpenAlex.
- Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASbioRxiv : the preprint server for biology · 2026Article
- Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.iScience · 2026Review
- FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.EMBO reports · 2026Article
- PD-L1 expression in primary lung tumor as a superior predictive biomarker to metastatic lymph nodes for first-line immunochemotherapy in advanced KRAS-mutant non-small cell lung cancer.Translational lung cancer research · 2025Article
- Distinct molecular subtypes of KRASClinical and translational medicine · 2025Article
- Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C.Cancer discovery · 2025Article
- Oncogenic mutant KRAS inhibition through oxidation at cysteine 118.Molecular oncology · 2025Article
- MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.Signal transduction and targeted therapy · 2024Review
- Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.Nature communications · 2024Article
- Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.Cancer science · 2024Article
- Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse.Cold Spring Harbor perspectives in medicine · 2024Review
- Using 3-Dimensional Cultures to Propagate Genetically Modified Lung Organoids.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.Cancer research · 2023Article
- A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.Biomolecules · 2023Article
- G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer.bioRxiv : the preprint server for biology · 2023Article
- Prognostic Role ofDiagnostics (Basel, Switzerland) · 2023Review
- Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.International journal of molecular sciences · 2023Review
- Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Molecular cancer therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 3 countries.
Shuai Li *Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Shengwu Liu *Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Jiehui DengDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Esra A AkbayDepartment of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas; Simmons Comprehensive Cancer Center, Dallas, Texas.
Josephine HaiDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Chiara AmbrogioDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4122-701X
Long ZhangDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Fangyu ZhouDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Russell W JenkinsDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Dennis O AdeegbeDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Peng GaoDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Xiaoen WangDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Cloud P PaweletzDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Grit S Herter-SprieDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ting ChenLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Laura Gutiérrez-QuicenoLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Yanxi ZhangDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Ashley A MerlinoDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Max M QuinnDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Yu ZengDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaoting YuDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Yuting LiuDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Lichao FanDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Andrew J AguirreDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
David A BarbieDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Xianghua YiDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China. Kwok-Kin.Wong@nyumc.org yixhxf@163.com.
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org yixhxf@163.com.
Dana-Farber Cancer Institute · USTongji University · CNNYU Langone Health · USHarold C. Simmons Comprehensive Cancer CenterMassachusetts General Hospital · US
Funding
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI ECK, MICHAEL J · 2012 to 2021
$17.8MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTargeting novel therapeutic vulnerabilities in LKB1 mutant tumors.R01CA219670 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL, WONG, KWOK KIN · 2018 to 2022
$3.4MTargeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung CancerU01CA213333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRAY, NATHANAEL SCHIANDER, WONG, KWOK KIN · 2017 to 2021
$3.3MTherapeutic approaches for LKB1-deficient non-small cell lung cancerR01CA205150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2016 to 2020
$3.0MCredentialing Mouse Models for Immune System Therapy ResearchR01CA195740 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, WONG, KWOK KIN · 2015 to 2017
$1.8MFunctional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancerK08CA218420 · NCI · DANA-FARBER CANCER INST · PI AGUIRRE, ANDREW JAMES · 2017 to 2021
$886kNCI NIH HHS K08 CA218420NCI NIH HHS P01 CA154303NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA195740NCI NIH HHS R01 CA205150NCI NIH HHS R01 CA219670NCI NIH HHS U01 CA213333
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllograftsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCell Line, TumorCell ProliferationDisease Models, AnimalFemaleHumansLung NeoplasmsMaleMAP Kinase Kinase Kinase 1MAP Kinase Signaling SystemMiceMiddle AgedMutationAZD 6244BenzimidazolesKRAS protein, humanMAP Kinase Kinase Kinase 1Protein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.